Zymeworks

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zymeworks and other ETFs, options, and stocks.

About ZYME

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2).

CEO

Kenneth Harry Galbraith

CEOKenneth Harry Galbraith

Employees

286

Employees286

Headquarters

Middletown, Delaware

HeadquartersMiddletown, Delaware

Founded

2003

Founded2003

Employees

286

Employees286

ZYME Key Statistics

Market cap

910.48M

Market cap910.48M

Price-Earnings ratio

-8.61

Price-Earnings ratio-8.61

Dividend yield

—

Dividend yield—

Average volume

536.15K

Average volume536.15K

High today

$13.25

High today$13.25

Low today

$12.78

Low today$12.78

Open price

$13.13

Open price$13.13

Volume

311.41K

Volume311.41K

52 Week high

$17.70

52 Week high$17.70

52 Week low

$8.83

52 Week low$8.83

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

28.6%

Sell

People also own

Based on the portfolios of people who own ZYME. This list is generated using Robinhood data, and it’s not a recommendation.